Elicera Therapeutics AB (publ) announced that it has received a so called "Notice of Allowance" from the Chinease Patent Office in its patent application relating to the use of the iTANK-technology in CAR T-cell therapies. Once granted, the patent can be kept in force until 2036.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.03 SEK | +3.21% | +14.70% | -77.41% |
03-28 | Elicera Therapeutics AB Announces Director Changes | CI |
03-06 | Elicera Enters Agreement with Prominent US Cancer Center to Evaluate the Use of ITANK in T-Cell Receptor Therapies | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-77.41% | 3.28M | |
+34.35% | 705B | |
+30.88% | 583B | |
-3.49% | 364B | |
+20.15% | 332B | |
+6.19% | 291B | |
+15.11% | 238B | |
-3.15% | 210B | |
+10.45% | 209B | |
+9.21% | 169B |
- Stock Market
- Equities
- ELIC Stock
- News Elicera Therapeutics AB
- Elicera Therapeutics Receives Notice of Allowance for Chinease Patent Protecting the iTANK Platform